Table 3 Determinants of the eGFR - Adjusted mixed effect linear regression
Covariates | β Estimate (95% CI) | P-value |
|---|---|---|
Follow-up time (months) | −0.63 (− 0.81, − 0.46) | < 0.001 |
Period after AVF (ref. before) | 0.94 (0.61, 1.26) | < 0.001 |
Follow-up time * period after AVF (ref. before) | 0.19 (0.16, 0.22) | < 0.001 |
Female | −0.69 (−1.48, 0.11) | 0.09 |
Age (per 5-year increase) | 0.03 (−0.13, 0.18) | 0.73 |
Follow-up time * Age | 0.02 (0.01–0.04) | 0.001 |
Black race (ref. White/other) | 2.73 (0.89, 4.57) | 0.004 |
Follow-up time * Black race | −0.20 (−0.35, − 0.05) | 0.01 |
RAAS blockade use | 1.82 (0.89, 2.75) | < 0.001 |
Diabetes | 0.87 (0.03, 1.71) | 0.04 |